Fig. 5: Effect of RIPK1 inhibition by Necrostatin 1.
From: The role of RIPK1 mediated cell death in acute on chronic liver failure
Histological assessment and biomarkers show the protective effect of pharmacological RIPK1 inhibition against ACLF-related liver injury. A Representative images of liver tissue of sham, BDL, BDL + LPS and BDL + NEC-1 + LPS stained for TUNEL, RIPK1, cleaved-Caspase 3 and 8. B The optical density of immunostaining intensity (mean ± SEM) was assessed by Image J (mean ± SEM). D Plasma levels of AST and albumin of sham, BDL, BDL + LPS, and BDL + NEC-1 + LPS (mean ± SEM). C–E Plasma levels of ALT, albumin, RIPK3 and histone 3 of sham, BDL, BDL + LPS and BDL + NEC-1 + LPS (mean ± SEM). Data were analyzed using Student’s t test or Mann–Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.
